^
Association details:
| Biomarker: | FGFR1 amplification |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | letrozole (Aromatase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial.
Published date:
05/16/2018
Excerpt:
We performed molecular analyses of primary BC from postmenopausal patients (pts) enrolled in the extended adjuvant intermittent letrozole vs. continuous letrozole...FGFR1 CNG was associated with worse outcomes (BCFI: HR = 3.2; 95% CI, 1.5-6.9, p = 0.003; and DRFI: HR = 3.5; 95% CI, 1.6-7.7, p = 0.002).
DOI:
10.1200/JCO.2018.36.15_suppl.517
Trial ID:
